Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138951 | 0.84 | TGFBR1 (0.67) | TGFBR1MAPK14MTOR | |
| SCHEMBL4906300 | 0.81 | TGFBR1 (0.39) | TGFBR1MAPK14MTORPIM1 | |
| SCHEMBL4902499 | 0.81 | TGFBR1 (0.46) | TGFBR1MAPK14MTORPIM1 | |
| SCHEMBL5138415 | 0.81 | TGFBR1 (0.67) | TGFBR1MAPK14MTORPIM1 | |
| SCHEMBL4898477 | 0.78 | KDM4E (0.67) | KDM4EALDH1A1POLBDYRK1ADYRK1B | |
| SCHEMBL5138443 | 0.77 | TGFBR1 (0.46) | TGFBR1MAPK14MTORKDM4EPOLB | |
| SCHEMBL5138799 | 0.76 | TGFBR1 (0.69) | TGFBR1MAPK14MTORPIM1 | |
| SCHEMBL4896435 | 0.72 | TGFBR1 (0.46) | TGFBR1MAPK14DYRK1A | |
| SCHEMBL5139942 | 0.72 | TGFBR1 (0.58) | TGFBR1MAPK14POLB | |
| SCHEMBL29832794 | 0.72 | TGFBR1 (0.58) | TGFBR1MAPK14POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | claimed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | TGFBR1 1/4885MAPK14 843/4885MTOR 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.